PBIGF
Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q2 | -0.06 | $25,139 | $0 |
| 2025 Q4 | -0.03 | $35,420 | -$8M |
| 2024 Q2 | -0.02 | $16,700 | -$8M |
| 2024 Q4 | -0.03 | $65,800 | $0 |
| 2023 Q2 | -0.17 | $0 | -$51M |
| 2023 Q4 | -0.07 | $42,050 | -$27M |
| 2022 Q2 | -0.12 | $4,710 | -$18M |
| 2022 Q4 | -0.05 | $34,024 | -$15M |